Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies.
BACKGROUND
Bolivia is a high tuberculosis (TB) incidence country with a large private for-profit health sector. TB drug sales in private pharmacies are not illegal.


OBJECTIVE
To measure the availability of TB drugs in private pharmacies, study vendors' attitudes, and explore the potential for collaboration between the public health sector and pharmacies.


METHODS
Simulated clients visited a random sample of 100 pharmacies in the city of Cochabamba, presenting with a prescription for four TB drugs. After the survey, contacts were made with the local Pharmacist's Association.


RESULTS
Twenty-five pharmacies sold at least one drug, 23 sold rifampicin and 16 sold isoniazid. Of 99 pharmacies unable to fill the whole prescription, 59 referred the client to another pharmacy, and 22 to the public services. Pharmacists said that rifampicin was often prescribed for non-TB indications, and that TB drug sales were of minimal contribution to their income. They agreed to stop selling the drugs and to refer clients seeking them to the public sector.


CONCLUSIONS
This study has documented a small market for TB drugs sales in private pharmacies and provided the opportunity to start collaboration with the pharmacists. Our results suggest that the private sector contributes little to managing TB in Bolivia.
Lambert
M L
ML
Epidemiology Unit, Public Health Department, Institute for Tropical Medicine, Antwerp, Belgium. mllambert@itg.be
Delgado
R
R
Michaux
G
G
Volz
A
A
Van der Stuyft
P
P
D000995:Antitubercular Agents / Q000627:therapeutic use*; D001838:Bolivia / Q000453:epidemiology; D003140:Communicable Disease Control; D003157:Community Pharmacy Services / Q000458:organization & administration*; D003299:Cooperative Behavior; D011307:Drug Prescriptions; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D010594:Pharmacies / Q000458:organization & administration*; D011306:Prescription Fees; D017149:Private Sector; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin